Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to its investigational therapy, CABA-201. This designation …
Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy Read More
KING OF PRUSSIA, PA — A recent survey sponsored by CSL Behring has illuminated the treatment preferences and concerns of patients living with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare …
Survey Reveals Unmet Needs in Treatment for Rare Nerve Disorder Read More
The U.S. Food and Drug Administration (FDA) recently approved Ogsiveo (nirogacestat) tablets for the systemic treatment of adult patients with progressing desmoid tumors, marking it as the first drug to …
FDA Approves Ogsiveo, First-Ever Drug for Treatment of Desmoid Tumors Read More